Eligibility-Aware Evidence Synthesis: An Agentic Framework for Clinical Trial Meta-Analysis
Fuente:
arXiv
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Preprint |
| Pubblicazione: |
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866917382624116736 |
|---|---|
| author | Zhao, Yao Zhang, Zhiyue Xu, Yanxun |
| author_facet | Zhao, Yao Zhang, Zhiyue Xu, Yanxun |
| contents | Clinical evidence synthesis requires identifying relevant trials from large registries and aggregating results that account for population differences. While recent LLM-based approaches have automated components of systematic review, they do not support end-to-end evidence synthesis. Moreover, conventional meta-analysis weights studies by statistical precision without considering clinical compatibility reflected in eligibility criteria. We propose EligMeta, an agentic framework that integrates automated trial discovery with eligibility-aware meta-analysis, translating natural-language queries into reproducible trial selection and incorporating eligibility alignment into study weighting to produce cohort-specific pooled estimates. EligMeta employs a hybrid architecture separating LLM-based reasoning from deterministic execution: LLMs generate interpretable rules from natural-language queries and perform schema-constrained parsing of trial metadata, while all logical operations, weight computations, and statistical pooling are executed deterministically to ensure reproducibility. The framework structures eligibility criteria and computes similarity-based study weights reflecting population alignment between target and comparator trials. In a gastric cancer landscape analysis, EligMeta reduced 4,044 candidate trials to 39 clinically relevant studies through rule-based filtering, recovering all 13 guideline-cited trials. In an olaparib adverse events meta-analysis across four trials, eligibility-aware weighting shifted the pooled risk ratio from 2.18 (95% CI: 1.71-2.79) under conventional Mantel-Haenszel estimation to 1.97 (95% CI: 1.76-2.20), demonstrating quantifiable impact of incorporating eligibility alignment. EligMeta bridges automated trial discovery with eligibility-aware meta-analysis, providing a scalable and reproducible framework for evidence synthesis in precision medicine. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2604_02678 |
| institution | arXiv |
| publishDate | 2026 |
| record_format | arxiv |
| spellingShingle | Eligibility-Aware Evidence Synthesis: An Agentic Framework for Clinical Trial Meta-Analysis Zhao, Yao Zhang, Zhiyue Xu, Yanxun Methodology Artificial Intelligence Applications Clinical evidence synthesis requires identifying relevant trials from large registries and aggregating results that account for population differences. While recent LLM-based approaches have automated components of systematic review, they do not support end-to-end evidence synthesis. Moreover, conventional meta-analysis weights studies by statistical precision without considering clinical compatibility reflected in eligibility criteria. We propose EligMeta, an agentic framework that integrates automated trial discovery with eligibility-aware meta-analysis, translating natural-language queries into reproducible trial selection and incorporating eligibility alignment into study weighting to produce cohort-specific pooled estimates. EligMeta employs a hybrid architecture separating LLM-based reasoning from deterministic execution: LLMs generate interpretable rules from natural-language queries and perform schema-constrained parsing of trial metadata, while all logical operations, weight computations, and statistical pooling are executed deterministically to ensure reproducibility. The framework structures eligibility criteria and computes similarity-based study weights reflecting population alignment between target and comparator trials. In a gastric cancer landscape analysis, EligMeta reduced 4,044 candidate trials to 39 clinically relevant studies through rule-based filtering, recovering all 13 guideline-cited trials. In an olaparib adverse events meta-analysis across four trials, eligibility-aware weighting shifted the pooled risk ratio from 2.18 (95% CI: 1.71-2.79) under conventional Mantel-Haenszel estimation to 1.97 (95% CI: 1.76-2.20), demonstrating quantifiable impact of incorporating eligibility alignment. EligMeta bridges automated trial discovery with eligibility-aware meta-analysis, providing a scalable and reproducible framework for evidence synthesis in precision medicine. |
| title | Eligibility-Aware Evidence Synthesis: An Agentic Framework for Clinical Trial Meta-Analysis |
| topic | Methodology Artificial Intelligence Applications |
| url | https://arxiv.org/abs/2604.02678 |